Weight loss technology for people with treated type 2 diabetes: a randomized controlled trial by Oshakbayev, Kuat et al.
RESEARCH Open Access
Weight loss technology for people with
treated type 2 diabetes: a randomized
controlled trial
Kuat Oshakbayev1* , Bibazhar Dukenbayeva2, Gulnar Togizbayeva3, Aigul Durmanova4, Meruyert Gazaliyeva5,
Abdul Sabir6, Aliya Issa7 and Alisher Idrisov8
Abstract
Background: The prevalence of type 2 diabetes is increasing in worldwide despite the development of new
treatment methods. Aim of the study was to evaluate a weight loss method on body composition, glycemic, lipid
and hormone profiles, blood pressure and reactive oxygen species in people with treated type 2 diabetes.
Methods: A 24-week open, prospective, randomized, controlled clinical trial including 272 adult patients with
treated type 2 diabetes was performed. The patients were divided in two groups: Main group consisted of 208
patients who followed a method including a calorie restriction diet and optimal physical activity; Control included
64 patients who received conventional drug treatment with weight loss. Main Outcome Measures were weight loss,
fasting glucose and 2-hour oral glucose tolerance test (OGTT), HbA1c. Secondary endpoints were blood pressure,
lipid and insulin blood levels.
Results: At 24 weeks, patients in Main weight lost between 8-18 kg (10–21%); their body mass index significantly
decreased (-4.2 kg/m2) as well as their waist circumference (-13 cm) compared to Control. In Main weight loss was
achieved fatty mass reduction. In Main fasting glucose and OGTT, HbA1c, blood pressure, reactive oxygen species
decreased significantly, whereas hemoglobin levels and heel bone mineral density increased. In Main blood insulin
levels decreased by 72.0%, cortisol levels decreased by 40.7%, while testosterone levels in men increased by 2.4
times from baseline. The application of the weight loss method led to a decrease in drug doses leading to their
complete withdrawal.
Conclusions: The results of this study show the beneficial role of a weight loss method in improving glycemic,
lipid and hormone profiles, electrolyte and biochemical indices, blood pressure, reactive oxygen species and bone
mineral density in patients with treated type 2 diabetes.
Trial registration: ClinicalTrials.gov Identifier: NCT02503865. Retrospectively registered November 2015.
Keywords: Type 2 diabetes, Weight loss, Restriction diet, Glycemic/lipid and hormone profiles, Lipid/protein
oxidation
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Background
In 2015, an estimated 422 million people had diabetes
worldwide [1], with T2D making up to about 90% of the
cases [2]. Diabetes is a major cause of blindness, kidney
failure, heart attacks, stroke and lower limb amputation,
and affects 8.5% of the adult population with equal
prevalence in both women and men [3]. Diabetes triples
the risk of cardiovascular diseases and doubles the risk
of death [4]. Prevalence of T2D is increasing worldwide
despite the development of new drugs.
Obesity/overweight is a major risk factor for T2D
[5, 6]. For instance, just 5% weight reduction im-
proves glycemic control in people with T2D [1, 6].
Effectiveness and types of weight loss approches in
people with T2D are increasingly reported in the lit-
erature. and many tested weight loss methods have
been proved to be less effective [4–6]. A systematic
review of weight loss interventions in people with
T2D revealed that interventions including very low-
calorie diets along with moderate physical activity
produced the largest effect [7, 8]. Although numerous
studies have attempted to identify the optimal mix of
lifestyle behavior for people with T2D, the optimal
level of caloric restriction in T2D is not well defined.
Moreover many of them do not include taking of sodium
and androgen-safety behavior during weight loss. We have
obtained positive results in people with T2D including
those who are insulin-dependent, using a weight loss
method that we developed. Objective: to evaluate the ef-
fects of our weight loss method on glycemic, lipid and
hormone profiles, blood pressure (BP), reactive oxygen
species level (ROS) and body composition in people with
treated T2D in a 24-week open, prospective, randomized,
controlled clinical trial.
Methods
Participants
The study enrolled 296 adult people aged from 25 to
74 years with treated T2D. All the participants had hyper-
tension. The patients were randomly recruited and divided
in two groups: Main group (Experimental): non-
pharmacological weight loss; Control group (Conventional):
conventional drug therapy with weight loss medication.
Main group included 224 patients who were taking anti-
diabetes drugs at least 3 years prior to first visit. Of these
224 patients, 7.1% dropped out prior to the study comple-
tion: 6 patients moved to live on another town, 8 patients
refused treatment through the weight loss method and 2
patients were excluded due to noncompliance. Therefore
208 patients (109 women, mean age 47.7 ± 1.8 years) with
T2D were followed up. All these 208 patients had abdom-
inal obesity with waist circumference (WC) 99.2 ± 0.6 cm
and body mass index (BMI) 29.6 ± 0.4 kg/m2. 152 patients
were on insulin (24–72 units/day), 56 patients were
treated with Metformin, Sulfonylurea, incretines [exena-
tide (Byetta, Bydureon), liraglutide (Victoza)], Pioglitazone
in different combinations.
Control group included 72 patients; 11.1% of them
dropped out prior to study completion (2 patients
moved to another town, 5 patients refused treatment,
and one was excluded due to noncompliance). Thus 64
patients (34 women, mean age 46.5 ± 2.1 years, WC 98.9
± 0.8 cm, BMI 29.3 ± 0.9 kg/m2) were recruited and
treated with conventional drug therapy including hypo-
glycemics (metformin 500–1500 mg/day, exenatide 5–
10 μg/day), lipid lowering (atorvastatin 40 mg/day),
antihypertensive (lisinopril 20 mg/day, calcium channel
blockers referring to benzodiazepines 90 mg/day) and
anti-inflammatory (acetylsalicylate acid up to 2 g/day
and/or thienopyridine class antiplatelet agent 75 mg per
day) drugs, and a gastrointestinal lipase inhibitor for
obesity management (orlistat 360 mg/day orally within
one hour of completing a meal). 41 of these 64 patients
were on insuli (24–72 U/day).
The study was carried out in Kazakhstan between
January 2003 and December 2014 at the Scientific
Research Institute of Cardiology and Internal Diseases
(Almaty) and at the Nazarbayev University Medical
Center (Astana).
Inclusion criteria
1) written informed consent form; 2) diagnosis of T2D ≥
3-year and treatment with glucose lowering therapy; 3)
triglycerides > 1.7 mmol/l or cholesterol > 5.6 mmol/l or
both); 4) body fat% > 21; 5) WC > 94.0 cm in men or >
80.0 cm in women; 6) ongoing treatment with antihyper-
tensive treatment; 7) weight loss treatment for 24 weeks
and follow-up ≥ 24 weeks.
Outcome measures
Primary endpoints: weight loss over 24 weeks, fasting
blood glucose and 2-hour oral glucose tolerance test
(OGTT), HbA1c. Secondary endpoints were systolic/dia-
stolic BP, blood lipids, blood insulin levels.
Randomization
An independent statistician unconnected with clinical
practice prepared randomization lists of patients with
T2D using computer generated random numbers (SPSS
for Windows v.21.0: An IBM Company, Armunk, NY).
Analytical assessment
T2D was diagnosed according to the criteria reported in
the WHO/IDF 2006 consultation [WHO/IDF consult-
ation. Geneva, Switzerland, 2006]. Hypertension was di-
agnosed by BP readings and from medical records.
Abdominal obesity was assessed by WC using the stan-
dards for Asians developed by the International Diabetes
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Federation (2005). Physical activity of patients was
assessed by the number of steps measured by pedome-
ters (Hoffmann-La Roche Ltd, Basel, Switzerland).
Anthropometrical indicators included age (years), weight
(kg), BMI (kg/m2), WC (cm). Body composition parameters
including fat mass (in % of total body weight and total kg),
visceral fat rating (units), fat free mass (kg), total body water
(% and kg), muscle mass (% and kg), bone mass (% and kg),
metabolic age (years), basal metabolic rate (kcal/day), and
bioimpedance (Ohms) were measured using a Tanita-
SC330S Body Composition Analyzer (Tanita Corp., Tokyo,
Japan). On the same blood samples, complete blood cell
count, erythrocyte sedimentation rate, urea, creatinine, glu-
cose, electrolytes, total cholesterol, triglycerides, total pro-
teins with fractions, fibrinogen, bilirubin, hepatic enzyme
levels and HbA1c [normal: < 39 mmol/mol (5.7%); predia-
betes: 39 to 48 mmol/mol (5.7–6.5%), diabetes: ≥ 48 mmol/
mol (6.5%)] were determined. Post oral glucose load insulin
sensitivity was determined using the 2-hour OGTT with
75 g of glucose. Ultrasound images (GE Vivid 7 Ultrasound;
GE Healthcare Worldwide USA, Michigan) were obtained,
and heel bone mineral density (HBMD) was measured
using a Lunar Achilles Express Ultrasound densitometry
(GE Healthcare USA, Madison; at normal range 100.0 ±
15.0 Units). Sodium excretion was considered high when
>150.0 mmol/L for both genders in 24-hour collected urine
(normal 135–145 mmol/L).
For ROS we measured malondialdehyde (MDA, a
marker of lipid peroxidation and degradation product of
oxidized fatty acids), superoxide dismutase and catalase
(antioxidant enzymes), and advanced oxidation protein
products (AOPP, markers of protein oxidation). MDA
(μmol/L) was measured using a thiobarbituric acid-
reactive substance assay as described by Yagi and modi-
fied by Ohkawa [9].
Antioxidant enzymes were determined in erythrocyte
hemolysates, in which hemoglobin concentration was
assayed using Drabkin’s method. Superoxide dismutase
was measured by the method of Misra and Fridrovich
[10]. Catalase was measured at λ =240 nm at 25 °C; cata-
lase activity was expressed in U/g and one unit is consid-
ered as the amount of the enzyme which decomposes 1 g
of H2O2 in 1 min at 25 °C in pH =7.0. AOPP (μmol/L)
were measured by adding 40 μL of plasma to a 190 μL of
mixture of 81% phosphate buffer solution, 10% glacial
acetic acid and 4% 1.16 mmol solution of KI, followed by
2 min absorbance at 340 nm on a plate reader Multiscan
Ascent using a spectrophotometric method. Chloramine-
T solution was used as calibrator [11].
Hormonal assays
Fasting serum insulin (nU/L) was determined by immuno-
assay (Immunotech Insulin Irma kit, Prague, Czech
Republic). Hyperinsulinemia was considered >12.5 nU/L.
The Homeostasis Model Assessment insulin resistance
indexes (HOMA-IR) was used as surrogate measure of
insulin sensitivity as follows: HOMA-IR = ((fasting insu-
lin in nU/L) × (fasting glucose in mmol/l)/22.5). Insulin
resistance was considered if the index was > 2.
Fasting serum cortisol was determined using solid-
phase chemiluminescent enzyme immunoassay (Corti-
sol-IFA-Best kit, Russia) on Sunrise Tecan-5082
(Austria, Gmbh) at 450 nm (limit of detection was
5 nmol/L; measurement ranges were 0–1200 nmol/L.
normal ranges 150–660 nmol/L).
Fasting total serum testosterone was assayed using
standard solid-phase radioimmunoassay (Biermann DPC,
Germany) procedures with a limit of detection < 4 ng/dL,
290–1290 ng/dL were normal values.
The hormones were investigated three days after stop-
ping the treatment.
Intervention
For weight loss in Main group we used the “Analimen-
tary detoxication” (ANADET) weight loss method [12],
including calorie restriction to 100–150 kcal/day with
fat-free vegetables (tomatoes and cucumbers), salt intake
limitation to 5–6 g/day, walking at least 8000 steps/day,
and sexual self-restraint. The exercise was promoted to
favor blood circulation and decrease metabolic intoxica-
tion. The weight loss method consisted of two courses
of “treatment” that lasted 14–28 days each according to
the principle “the slower the weight loss, the longer its
duration”, with a two-week interruption between the
courses. Then the patients followed a diet where they
ate one meal a day without any food restriction. A com-
bination of in-person conversations and telephone calls
were conducted during the 24-week study period and a
24-week follow-up period. Weight loss results were
assessed by Tanita-SC330S, BMI, WC, and skinfold
thickness measurement method (cm) in abdominal and
the back areas. The method maintains an achieved target
weight loss for ≥ 24 weeks.
Statistics
The two-side Student’s t-test and Odds ratios (ORs) with
95% Confidence intervals (CIs) were used. The study
data were tested against the normal distribution and are
presented in Tables as Mean ± Standard Error of the
Mean (M ± SEM), and in Figures as Mean ± Standard
Deviation (M ± SD). The formula for the SEM is the SD
divided by the square root of the sample size. The cor-
relation analysis (r) and an analysis of covariance
(ANCOVA) model were used. P-value of < 0.05 was set
as significant and < 0.0001 was set as highly significant.
Statistical analysis was performed using SPSS ver.21.0
for Windows (SPSS: An IBM Company, Armunk, NY)
and Microsoft Excel-2013.
Oshakbayev et al. Nutrition & Metabolism  (2017) 14:11 Page 3 of 9
Results
Baseline/24-week treatment results concerning anthropo-
metrical data, body composition, and metabolic data in
the compared groups are shown in Table 1. In Main group
weight loss varied from 8 to 18 kg (− 10–21% from base-
line) and was higher than Control at 24-week (−12.8 ±
0.8 kg vs. -3.2 ± 0.9 kg, respectively; P < 0.00001). In Main
we observed a significantly decrease in BMI (−4.2 kg/m2)
and WC (−13 cm), skinfold thickness in abdomen and the
back areas (−1.4 cm). Figure 1 shows adjusted mean differ-
ences in Main vs. Control from baseline in Anthropome-
trical data at 24-week. In Main weight loss was due to
reduction of fat mass only (before, 25.41 ± 0.65 kg, and
after, 12.38 ± 0.68 kg, P < 0.00001). Percentages of total
body water and muscle masses tended to increase signifi-
cantly, and the percentage of bone mass increased signifi-
cantly too. Lean body mass (fat-free mass) did not change
significantly during weight loss (P = 0.9225). Figure 2
shows adjusted mean difference from baseline Body com-
position in group Main vs Control at 24-week.
In Main group there was an inverse relationship between
Fat mass percentage and Metabolic age/Basal metabolic rate
(r= − 0.58, P= 0.0014 and r= − 0.68, P= 0.0009, respect-
ively). Bioimpedance, electrical conductivity also improved.
The ANADET (Main group) led to a 15–19% decrease
in systolic/diastolic BP in 199 patients (95.8%) (Table 2).
Fasting Glucose, 2-hour OGTT, HbA1c and systolic BP
decreased in Control, but to a lesser extent. In Control
diastolic BP decreased less and did not reach the level rec-
ommended by the American Heart Association (2014).
Hemoglobin, Catalase and HBMD levels did not
change in Control, whereas in Main group hemoglobin
levels increased by +9.5% and erythrocyte sedimentation
rate and eosinophilia decreased from baseline by 67.5
and 66.0%, respectively. In Main group there was a re-
duction of fasting glucose (−47.9%), OGTT (2.2-fold),
HbA1c (−22%), Cholesterol (−22.0%), Triglycerides
(−66.5%), total Fibrinogen (−51.1%) (P < 0.0001). In Con-
trol HbA1c decreased by 8% (P < 0.05), but did not reach
to the normal.
The oxidative products of lipids and proteins were
also normalized in Main group, where MDA de-
creased by 30.9%, AOPP by 31.9%, and Superoxide
dismutase increased by 44.4% and Catalase by 19.3%
from baseline. Urine sodium excretion decreased by
80.3% after weight loss, while blood sodium increased by
6.7%. HBMD increased significantly (+19.7%) from base-
line (P < 0.00001). In contrast, in Control there were a
Table 1 Anthropometrical data, body composition, Metabolic age, Basal metabolic rate in people with treated T2D before (baseline)
and after treatment (24-week) within Main (Experimental) and Control (Conventional) groups (M ± SEM)
Variables Main group, n = 208 Control group, n = 64
Baseline 24-Week Baseline 24-Week
Passport age (years) 47.69 ± 1.82 46.54 ± 2.08
Weight (kg) 84.52 ± 0.75 72.44 ± 1.02** 84.49 ± 0.81 81.35 ± 1.23*
BMI (kg/m2) 29.60 ± 0.39 25.40 ± 0.37** 29.30 ± 0.47 28.04 ± 0.55
WC (cm) 99.18 ± 0.56 86.13 ± 0.93** 98.91 ± 0.83 95.38 ± 0.78*
Skinfold thickness in
the areas of (cm):
Abdomen 3.96 ± 0.04 2.52 ± 0.05** 4.02 ± 0.07 3.69 ± 0.08*
The back 4.41 ± 0.04 3.14 ± 0.05** 4.38 ± 0.06 4.06 ± 0.07*
Fat mass (%) 30.06 ± 0.52 18.47 ± 0.67** 29.73 ± 0.88 28.04 ± 0.92
Fat mass (kg) 25.41 ± 0.65 13.38 ± 0.68** 25.12 ± 0.97 22.87 ± 1.12
Fat free mass (kg) 59.11 ± 0.32 59.06 ± 0.41 59.37 ± 0.79 58.68 ± 0.80
Total body water (kg) 44.58 ± 0.26 45.13 ± 0.32 44.65 ± 0.44 44.81 ± 0.46
Total body water (%) 52.74 ± 0.35 62.29 ± 0.43** 52.84 ± 0.57 54.94 ± 0.62*
Muscle mass (kg) 54.22 ± 1.14 55.39 ± 1.96 54.21 ± 1.76 54.19 ± 1.98
Muscle mass (%) 64.15 ± 1.21 76.46 ± 1.62** 64.27 ± 1.71 66.48 ± 1.82
Bone mass (kg) 3.18 ± 0.06 3.09 ± 0.10 3.17 ± 0.09 3.07 ± 0.10
Bone mass (%) 3.76 ± 0.08 4.26 ± 0.09** 3.75 ± 0.09 3.78 ± 0.11
Metabolic age (years) 52.12 ± 1.52 42.31 ± 1.68** 52.01 ± 1.87 50.11 ± 1.92
Basal metabolic rate (kcal/day) 1702.4 ± 43.25 1401.6 ± 48.56** 1700.6 ± 50.45 1639.2 ± 55.44
Bioimpedance (ohms) 512.5 ± 9.25 465.5 ± 9.15* 507.4 ± 14.43 496.2 ± 13.28
Abbreviations: BMI body mass index, M mean, SEM standard error of the mean, WC waist circumference, T2D type 2 diabetes
*P-value of < 0.05, and
**P < 0.0001 were set as significant between baseline and 24-week treatment within group comparison
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significant increase in eosinophilia, MDA, AOPP, and
urine sodium and s decrease in blood sodium.
In Main after treatment blood insulin decreased by
72.0%, cortisol decreased by 40.7%, whereas blood tes-
tosterone in men (n = 99) increased 2.4-fold from base-
line (Table 3). In Control, the positive changes in
hormones were not so evident. For instance, insulin in
Main decreased 3.6-fold from baseline after treatment,
whereas in Control it decreased only 1.4-fold (95%; OR
2.6, CI 2.1–3.1). Although in Control insulin levels did
not decrease to the normal. In addition, cortisol and tes-
tosterone levels did not change significantly in Control.
The Table 3 proves that in Main group tissue insulin
sensitivity improved following treatment, and IR
(HOMA-IR index) decreased significantly 6.8-fold from
baseline, whereas in Control it only decreased only 2-
fold (95%; OR3.2, CI2.8–3.3). In Control the HOMA-IR
index did not reach normal values (Fig. 3).
During the first 2–5 days of treatment most of the pa-
tients in Main complained of hunger, slight dizziness,
weakness, lower extremity and abdominal muscle tremor,
warm feeling in the umbilical/solar plexus areas, and psy-
chogenic fear due to changed eating behavior, which all
disappeared in the following days. 3–5 days after the start
of the ANADET patients’ urine became turbid, muddy
and intensively colored (dark). These urine appearance
persisted for several days. Urine microscopy showed or-
ganic salts such as oxalates, urates, phosphates, and car-
bonates of calcium and magnesium. An increase in body
temperature and blood leukocyte count was observed be-
tween 4 and 14 days after the start of ANADET. The co-
morbidity symptoms were also regressed gradually. The
patients noticed a physical relief, increase in physical/
mental workability, and exercise tolerance.
As the clinical status of the patients was improv-
ing, the previous anti-diabetic, antihypertensive and
Fig. 1 Adjusted mean differences in Anthropometrical data between baseline and week 24 in people with treated T2D in Main versus Control
groups (SPSS, ANCOVA), P < 0.0001 (M ± SD)
Fig. 2 Adjusted mean differences in Body composition between baseline and week 24 in people with treated T2D in Main versus Control groups
(SPSS, ANCOVA), P < 0.0001 (M ± SD)
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other symptomatic conventional medications were
adequately decreased from 2 to 3 days after start-
ing ANADET. By days 7 to 10 after the treatment start,
the drugs were stopped completely. There was no recur-
rence of T2D at 6 months follow-up period if the patients
had not regained overweight. If a patient regained over-
weight, symptoms of T2D gradually manifested again, and
once again disappeared once the overweight was lost
again.
Discussion
Our data show that weight loss method (10 to 21% fat
loss) including calorie restriction (100–150 kcal/day),
fat-free vegetables and salt intake (5–6 g/day), optimal
physical activity, and sexual self-restraint over a 24-week
period is a safe, well tolerated, and acceptable nutritional
therapy option for subjects with T2D. Our study con-
firms that weight loss can lead to normalization of BP
[13]. ANADET repealed insulin resistance, improved
Table 2 Blood pressures, Blood biochemical parameters, Lipid and protein oxidative products, Sodium excretion rate, and HBMD in
people with treated T2D before (baseline) and after treatment (24-week) within the Main (Experimental) and Control (Conventional)
groups (M ± SEM)
Variables Main group, n = 208 Control group, n = 64
Baseline 24-week Baseline 24-week
Systolic blood pressure (mmHg) 154.3 ± 1.22 120.4 ± 0.67** 150.4 ± 1.76 128.7 ± 2.17**
Diastolic blood pressure (mmHg) 98.7 ± 0.75 80.92 ± 0.63** 98.1 ± 0.98 93.2 ± 1.29*
Hemoglobin (g/L) 126.5 ± 0.68 138.9 ± 0.62** 127.1 ± 0.71 127.4 ± 0.72
ESR (mm/Hour) 23.4 ± 0.64 7.66 ± 0.26** 22.9 ± 0.70 24.8 ± 0.75*
Eosinophilia (%) 5.35 ± 0.21 1.82 ± 0.14** 5.29 ± 0.29 6.08 ± 0.30*
Glucose (mmol/L) 8.64 ± 0.19 4.50 ± 0.11** 8.58 ± 0.24 6.04 ± 0.21**
2-hour OGTT (mmol/L) 14.5 ± 0.28 6.7 ± 0.19** 14.1 ± 0.33 8.21 ± 0.42**
HbA1c (mmol/mol and %) 52.0 ± 0.68 (6.91 ± 0.09) 35.0 ± 0.52** (5.39 ± 0.08) 52.0 ± 1.13 (6.89 ± 0.15) 46.0 ± 1.15* (6.38 ± 0.16)
Cholesterol (mmol/L) 5.82 ± 0.07 4.54 ± 0.05** 5.77 ± 0.09 5.47 ± 0.11*
Triglyceride (g/L) 2.42 ± 0.08 0.81 ± 0.05** 2.21 ± 0.08 1.92 ± 0.12*
Total Fibrinogen (g/L) 4.52 ± 0.07 2.21 ± 0.06** 4.58 ± 0.09 4.05 ± 0.18*
MDA (μmol/L) 48.47 ± 0.68 33.48 ± 0.29** 46.99 ± 0.75 50.46 ± 0.79*
SOD (U/mg) 53.83 ± 0.54 77.71 ± 0.67** 52.91 ± 0.65 56.87 ± 0.97*
Catalase (U/g) 22.17 ± 0.42 26.44 ± 0.46** 23.81 ± 0.49 25.17 ± 0.68
AOPP (μmol/L) 266.8 ± 12.6 181.8 ± 7.8** 262.4 ± 13.6 295.6 ± 13.9*
Sodium in the urine (mmol/L) 164.1 ± 2.8 32.4 ± 1.9** 164.1 ± 2.8 182.4 ± 3.5**
Sodium in the blood (mmol/L) 134.4 ± 0.32 143.7 ± 0.38** 135.1 ± 0.35 134.1 ± 0.34*
HBMD (Units) 77.83 ± 1.86 93.2 ± 1.37** 78.78 ± 1.92 76.87 ± 1.88
Abbreviations: ANADET analimentary detoxication, AOPP advanced oxidation protein products, ESR erythrocyte sedimentation rate, HBMD heel bone mineral
density, M mean, MDA malondialdehyde, OGTT oral glucose tolerance test, SOD superoxide dismutase, SEM standard error of the mean, T2D type 2 diabetes
*P-value of < 0.05, and
**P < 0.0001 were set as significant between baseline and 24-week treatment within group comparison
Table 3 Immunoassays of blood Insulin, HOMA-IR, Cortisol and Testosterone (in men) in people with treated T2D before (baseline)
and after treatment (24-week) within Main (Experimental) and Control (Conventional) groups (M ± SEM)
Variables Main group, n = 208 Control group, n = 64
Baseline 24-week Baseline 24-week
Immunoassay insulin (nU/L) 23.2 ± 1.0 6.5 ± 0.3* 20.9 ± 1.2 15.0 ± 1.2*
Immunoassay cortisol (nmol/L) 751.2 ± 6.7 445.7 ± 5.3* 747.2 ± 8.9 739.5 ± 9.1
HOMA-IR index 8.9 ± 0.44 1.30 ± 0.29* 7.97 ± 0.53 4.03 ± 0.55*
Variable in men
Main group, n = 99 Control group, n = 30
Blood testosterone (ng/dL) 365.9 ± 13.8 885.2 ± 21.2* 379.2 ± 19.6 395.2 ± 24.5
Abbreviations: ANADET analimentary detoxication, HOMA-IR Homeostasis Model Assessment insulin resistance index, IR insulin resistance, M mean, SEM standard
error of the mean, T2D type 2 diabetes
*P < 0.0001 were set as significant between baseline and 24-week treatment within group comparison
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blood insulin levels, increased hemoglobin, and im-
proved inflammation parameters. Our results confirm
those of some other studies [7, 8, 14]. ANADET also de-
creased blood cholesterol/triglyceride levels and lipid
and protein oxidative products, and increased enzymes
against oxidative stress. Our study prove a potential val-
idity of the optimal mix of caloric restriction, walking,
sodium intake and sexual self-restraint behavior in ef-
fective treatment of T2D.
People with T2D eliminate through urine more so-
dium ions due to hyperglycemia-induced serum osmolal-
ity [15]. Blood and urine sodium became normal on a
weight loss method that decreased metabolic pollutants
[16], with elimination of metabolites [17]. The sodium
intake in Main group subjects with T2D helped to elim-
inate metabolic pollutants from the body.
ANADET method improved HBMD; notably, not all
weight loss methods increase HBMD [18].
People with T2D have high blood cortisol [19] and low
testosterone [20]. ANADET method improved both blood
cortisol and testosterone levels. Numerous studies involv-
ing both animal and human models indicate that diet-
induced weight loss is associated with positive changes in
leptin and ghrelin levels, insulin sensitivity and cytokine
patterns [21]. However, the reciprocal influences between
adiposity and hormones like insulin, leptin, ghrelin and
others remain unclear.
Overweight is a biological burden for the body consum-
ing additional trophic, immunological, antitoxic, excretion
function [22]. The ANADET method metabolizes of “old
lipids”, leading to loss of fat mass only and to increase in
muscle, water and bone masses. The patients experienced
side effects related to symptoms of metabolic intoxication
that is a common problem during weight loss. Adipose tis-
sue can indeed absorb different persistent organic pollut-
ants [23], and important role of adiposity in storing of
pollutants has been outlined [24, 25]. ANADET method
allows to: 1) control the elimination of metabolic end-
products; 2) switch on lipolysis; 3) reuse of interim metabo-
lites. Physical exercise and mandatory salt intake are
important to decrease in metabolic wastes. If sodium ions
are a main transporter in the body, then exercise improves
the endothelial nitric oxide and prostaglandins pathways
[26]. Sexual self-restraint allows to save endogenous andro-
gens in both genders [27, 28].
The ability to accumulate adipose tissue is one of the
most important adaptive mechanism for survival [29].
However, we are now observing a steady increase in
obesity and related diseases [1–4].
Study limitation
Published studies about positive role of weight loss in
people with T2D are limited in scope and number. A limi-
tation of our study is short duration. We acknowledge the
clinical trial had approximately 8% of the randomly
assigned population dropped out prior to completion. We
should perform a multicenter prospective clinical random-
ized controlled trial. Further research is needed.
Conclusions
In people with T2D an increased in fat mass is paralleled
by reduction in muscle, bone, and water masses. In-
creased fat mass leads to increase bioimpedance and
metabolic aging. Our results indicate that the weight loss
Fig. 3 Adjusted mean differences in Immunoassays Insulin, Cortisol and HOMA-IR between baseline and week 24 in people with treated T2D in
Main versus Control groups (SPSS, ANCOVA), P < 0.0001 (M ± SD)
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method called ANADET can be an effective treatment
for people with T2D. The method, aimed to cure and
control metabolic intoxication, improves glycaemia, in-
sulin resistance, lipids and hormones, electrolyte and
biochemical outcomes, reactive oxygen species, instru-
mental parameter, and allows drugs reduction up to its
complete withdrawal.
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